Top

Published in:

01-07-2010 | Original paper

History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study

Authors: Qiang Li, Shinichi Kuriyama, Masako Kakizaki, Hong Yan, Toshimasa Sone, Masato Nagai, Yumi Sugawara, Kaori Ohmori-Matsuda, Atsushi Hozawa, Yoshikazu Nishino, Ichiro Tsuji

Published in: Cancer Causes & Control | Issue 7/2010

Abstract

Objective

The association between diabetes mellitus and the risk of prostate cancer has been tested in previous prospective cohort studies in western populations. However, no evidence from cohort studies is available for Asian populations, whose lifestyle is very different from that of westerners.

Methods

The authors examined the relationship between diabetes mellitus and the risk of prostate cancer in the Ohsaki cohort followed from 1995 to 2003, in which 230 new cases of prostate cancer were identified among 22,458 Japanese men. Baseline information including diabetes mellitus status was collected using a self-administered questionnaire. The Cox proportional hazards regression model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

Although a history of diabetes mellitus was not associated with the risk of total prostate cancer in this population, after stratification based on the clinical stage of prostate cancer, patients with diabetes mellitus showed a higher risk of advanced prostate cancer with a multivariate adjusted HR = 1.89 (95% CI: 1.02–3.50). The relationship remained robust when we excluded from the analysis cases arising in the first 2 years.

Conclusion

This population-based prospective cohort study indicates that a history of diabetes mellitus is associated with an increased incidence of advanced prostate cancer.

King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431CrossRefPubMed

Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRefPubMed

Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90:162–173CrossRefPubMed

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H (2000) Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7:254–257CrossRefPubMed

The Editorial Board of the Cancer Statistics in Japan (2005) Cancer Statistics in Japan edition. Foundation for Promotion of Cancer Research, Tokyo

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed

Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169:937–945CrossRefPubMed

Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124:1398–1403CrossRefPubMed

Velicer CM, Dublin S, White E (2007) Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 10:46–51CrossRefPubMed

10.

Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, Hollenbeck A, Schatzkin A et al (2007) History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18:493–503CrossRefPubMed

11.

Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 161:147–152CrossRefPubMed

12.

Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102:258–261CrossRefPubMed

13.

Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1998) Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9:3–9CrossRefPubMed

14.

Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365CrossRefPubMed

15.

Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL III, Andriole GL (2008) Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control 19:1267–1276CrossRefPubMed

16.

Will JC, Vinicor F, Calle EE (1999) Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10:313–318CrossRefPubMed

17.

Steenland K, Nowlin S, Palu S (1995) Cancer incidence in the National Health, Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 4:807–811PubMed

18.

Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL (1989) Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 129:511–517PubMed

19.

Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13–19CrossRefPubMed

20.

Tsuji I, Nishino Y, Ohkubo T, Kuwahara A, Ogawa K, Watanabe Y, Tsubono Y, Bando T, Kanemura S, Izumi Y, Sasaki A, Fukao A et al (1998) A prospective cohort study on National Health Insurance beneficiaries in Ohsaki, Miyagi Prefecture, Japan: study design, profiles of the subjects and medical cost during the first year. J Epidemiol 8:258–263PubMed

21.

Tsuji I, Kuwahara A, Nishino Y, Ohkubo T, Sasaki A, Hisamichi S (1999) Medical cost for disability: a longitudinal observation of national health insurance beneficiaries in Japan. J Am Geriatr Soc 47:470–476PubMed

22.

Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I (2006) Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296:1255–1265CrossRefPubMed

23.

Kakizaki M, Inoue K, Kuriyama S, Sone T, Matsuda-Ohmori K, Nakaya N, Fukudo S, Tsuji I (2008) Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer 99:176–178CrossRefPubMed

24.

Li Q, Kakizaki M, Kuriyama S, Sone T, Yan H, Nakaya N, Mastuda-Ohmori K, Tsuji I (2008) Green tea consumption and lung cancer risk: the Ohsaki study. Br J Cancer 99:1179–1184CrossRefPubMed

25.

Ogawa K, Tsubono Y, Nishino Y, Watanabe Y, Ohkubo T, Watanabe T, Nakatsuka H, Takahashi N, Kawamura M, Tsuji I, Hisamichi S (2003) Validation of a food-frequency questionnaire for cohort studies in rural Japan. Public Health Nutr 6:147–157CrossRefPubMed

26.

Takano A, Okuno Y (1997) Japan, Miyagi Prefecture. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) Cancer incidence in five continents, vol. 7. IARC Sci Publ., Paris, pp 386–389

27.

Percy C, Holton VV (1990) International classification of diseases for oncology, 2nd edn. World Health Organization, Geneva

28.

Mishina T, Watanabe H, Araki H, Nakao M (1985) Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 6:423–436CrossRefPubMed

29.

Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401–407CrossRefPubMed

30.

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(461–471):W83–W88

31.

Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ (2003) Insulin resistance and prostate cancer risk. J Natl Cancer Inst 95:67–71PubMedCrossRef

32.

Zamboni PF, Simone M, Passaro A, Doh Dalla Nora E, Fellin R, Solini A (2003) Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res 35:296–300CrossRefPubMed

33.

Singh G, Lakkis CL, Laucirica R, Epner DE (1999) Regulation of prostate cancer cell division by glucose. J Cell Physiol 180:431–438CrossRefPubMed

34.

Seki A, Takigawa T, Ito T, Fukuoka E, Takahashi K, Kira S (2002) Obesity and the risk of diabetes mellitus in middle-aged Japanese men. Acta Med Okayama 56:255–260PubMed

35.

Porter MP, Stanford JL (2005) Obesity and the risk of prostate cancer. Prostate 62:316–321CrossRefPubMed

36.

Robinson WR, Stevens J, Gammon MD, John EM (2005) Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol 161:1107–1114CrossRefPubMed

37.

Bradbury BD, Wilk JB, Kaye JA (2005) Obesity and the risk of prostate cancer (United States). Cancer Causes Control 16:637–641CrossRefPubMed

38.

Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15:1977–1983CrossRefPubMed

39.

Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16:63–69CrossRefPubMed

40.

Wakai K (2005) Descriptive epidemiology of prostate cancer in Japan and Western countries. Nippon Rinsho 63:207–212PubMed

41.

Akazawa Y (1994) Prevalence and incidence of diabetes mellitus by WHO criteria. Diabetes Res Clin Pract 24(Suppl):S23–S27CrossRefPubMed

42.

Nakano T, Ito H (2007) Epidemiology of diabetes mellitus in old age in Japan. Diabetes Res Clin Pract 77(Suppl 1):S76–S81CrossRefPubMed

Title: History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study
Authors: Qiang Li
Shinichi Kuriyama
Masako Kakizaki
Hong Yan
Toshimasa Sone
Masato Nagai
Yumi Sugawara
Kaori Ohmori-Matsuda
Atsushi Hozawa
Yoshikazu Nishino
Ichiro Tsuji
Publication date: 01-07-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9530-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2010

Family history and lung cancer risk: international multicentre case–control study in Eastern and Central Europe and meta-analyses

Cancer risk in relationship to different indicators of adult socioeconomic position in Turin, Italy

Case–control study of lifetime total physical activity and endometrial cancer risk

Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population

Cancer risk in DES daughters

Meeting the cervical cancer screening needs of underserved women: The National Breast and Cervical Cancer Early Detection Program, 2004–2006

Keynote webinar | Spotlight on antibody–drug conjugates in cancer